United Therapeutics (UTHR) Tops Q2 EPS by 18c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
Revenue Growth %: -1.2%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: -1.2%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $7.27, $0.18 better than the analyst estimate of $7.09. Revenue for the quarter came in at $783.3 million versus the consensus estimate of $807.05 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- ADARx Pharmaceuticals files for proposed IPO
- Starlo to acquire Mexico silver project in reverse takeover deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
